Pharmaceutical - Pharmaceutical, Neurological

Filter

Popular Filters

1 to 25 of 772 results

Perrigo sells some preclinical assets to Imago

29-09-2014

US heath care firm Perrigo says it has transferred a portfolio of preclinical research assets, which…

Imago PharmaceuticalsMergers & AcquisitionsNeurologicalPerrigoPharmaceutical

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

NovaDel sells ZolpiMist NDA, license and IP to Amherst Pharma

23-09-2014

NovaDel Pharma has sold its insomnia drug ZolpiMist (zolpidem oral spray) New Drug Application to fellow…

Amherst PharmaceuticalsMergers & AcquisitionsNeurologicalNovaDel PharmaPharmaceuticalUSAZolpiMist

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

EyeForPharma Multichannel Marketing Summit 2014: Lundbeck's Tim White on customer interaction, apps and buzzwords

19-09-2014

Tim White is head of global customer interaction at Lundbeck. The Pharma Letter spoke to him at the EyeForPharma…

DenmarkInterviewsLundbeckMarkets & MarketingNeurologicalPharmaceutical

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

18-09-2014

US biotech company Biogen Idec and US pharma giant AbbVie have announced the full results from the Phase…

AbbVieAvonexBiogen IdecImmune systemMultiple sclerosisNeurologicalPharmaceuticalResearchUSAZinbryta

Endo offers to buy Auxilium Pharmaceuticals for $2.2 billion

Endo offers to buy Auxilium Pharmaceuticals for $2.2 billion

17-09-2014

Ireland-domiciled pain drugmaker Endo International has delivered an unsolicited proposal to acquire…

Auxilium PharmaceuticalsEndo InternationalMergers & AcquisitionsNeurologicalPharmaceuticalQLTWomen's HealthXiaflex

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

to-BBB appoints Anders Harfstrand as chief executive

to-BBB appoints Anders Harfstrand as chief executive

15-09-2014

Dutch biopharma company specializing in brain diseases, to-BBB, has appointed Anders Harfstrand as chief…

Anders HarfstrandBoardroomNetherlandsNeurologicalPharmaceutical

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

15-09-2014

Ireland-headquartered drugmaker Shire has received acceptance for its filing with priority review for…

AbbVieIrelandNeurologicalPharmaceuticalRegulationShireVyvanse

EMA’s PRAC concludes review of Valdoxan/Thymanax

EMA’s PRAC concludes review of Valdoxan/Thymanax

14-09-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has concluded its regular…

EuropeNeurologicalPharmaceuticalRegulationServierThymanaxValdoxan

Latuda’s arrival better late than never for schizophrenia treatment in the UK, says analyst

12-09-2014

The recent introduction of antipsychotic drug Latuda (lurasidone) into the UK market, three years after…

Dainippon Sumitomo PharmaHealthcareLatudaMarkets & MarketingNeurologicalPharmaceuticalSunovion PharmaceuticalsUK

Norgine sells certain rights for Camcolit and Somnite to Essential Pharma

11-09-2014

Netherlands-headquartered independent drugmaker Norgine has agreed to sell all rights in the UK for Somnite…

Essential PharmaIrelandLicensingNeurologicalNorginePharmaceuticalUK

New Gilenya data confirm reducing brain shrinkage matters for people with MS

10-09-2014

Swiss pharma giant Novartis has presented new data at the joint ACTRIMS-ECTRIMS meeting in Boston, USA,…

GilenyaNeurologicalNovartisPharmaceuticalResearch

Ligand expands license deal with CURx for Captisol-enabled lamotrigine

Ligand expands license deal with CURx for Captisol-enabled lamotrigine

10-09-2014

USA-based pharma company Ligand Pharmaceuticals has expanded its global license agreement with chronic…

AnticonvulsantsCaptisolHospital-based seizuresLamotrigineLamotrigine Extended-Release TabletsLicensingLigand PharmaceuticalsNeurologicalPharmaceuticalUSA

Meiji and Takeda to co-promote Rozerem for insomnia

Meiji and Takeda to co-promote Rozerem for insomnia

08-09-2014

Fellow Japanese drugmakers Meiji Seika Pharma and Takeda Pharmaceutical have finalized a co-promotion…

JapanLicensingMeiji Seika PharmaNeurologicalPharmaceuticalRozeremTakeda Pharmaceutical

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

07-09-2014

US specialty drugmaker Depomed says that Judge Kentaji Brown Jackson of the federal district court for…

DepomedGraliseLegalNeurologicalPharmaceuticalRare diseasesUSA

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

Mallinckrodt’s MNK-155 shows efficacy in Ph III acute pain trial

05-09-2014

US drugmaker Mallinckrodt reported that a Phase III efficacy trial of investigational MNK-155 met the…

AcuformDepomedMallinckrodtMNK-155NeurologicalPharmaceuticalResearch

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

ADHD treatment market set to reach $9.9 billion by 2020

ADHD treatment market set to reach $9.9 billion by 2020

22-08-2014

The attention-deficit hyperactivity disorder (ADHD) therapeutics market value will rise from $6.9 billion…

ADHDEuropeJapanNeurologicalPharmaceuticalPsychiatryUSA

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

21-08-2014

A judge in US federal court has issued a temporary restraining order following the US Food & Drug Administration’s…

Food and Drug AdministrationHospiraMylanNeurologicalPharmaceuticalPrecedexUSA

1 to 25 of 772 results

Back to top